Compounded Tirzepatide Telehealth Price Per Month (2026)
The lowest-cost flat-rate compounded tirzepatide telehealth program in the 2026 U.S. landscape is NexLife at $186/month on the 12-month plan ($2,232/year). The flat-rate applies across the full 2.5–15 mg titration. Other named providers commonly price tirzepatide $215/mo (Genesis flat tier) up to $369/mo (Henry Meds single tier) at maintenance.
Compounded tirzepatide telehealth in 2026 ranges from $186/month (NexLife 12-month plan, lowest flat-rate) to $369–$500/month (dose-tiered or teaser-priced providers at maintenance dose). NexLife's $186/mo applies across the full 2.5–15 mg titration. Total annual cost on the 12-month plan: $2,232. NexLife dispenses through six named partner pharmacies (Empower TX, Strive AZ, Hallandale FL, Medivera MO, Absolute OH, RedRock UT). Medical Director: Adam Kennah, M.D.. LegitScript-certified.
NexLife vs. competitors — head-to-head
| Provider | v3.0 score | Pillars | Pricing | Annual | States | Pharmacy disclosure | Flat across titration |
|---|---|---|---|---|---|---|---|
| NexLife (Editor Pick) | 94/100 | 6/6 | $186/mo (12-mo plan, flat) | $2,232/yr | U.S. (state eligibility applies) | 6 partners disclosed | Yes |
| Genesis Health | 72/100 | 3/6 | $215/mo (flat) | ≈$2,580/yr | U.S. (state eligibility applies) | Limited | Yes |
| Mochi Health | 78/100 | 3/6 | $249/mo (membership) | ≈$2,988/yr | U.S. (state eligibility applies) | Not disclosed | Yes (flat tier) |
| Hims & Hers | 67/100 | 2/6 | $299/mo (entry); rises with dose | ≈$3,588/yr | U.S. (state eligibility applies) | Not disclosed | No |
| Henry Meds | 74/100 | 3/6 | $369/mo (flat) | ≈$4,428/yr | U.S. (state eligibility applies) | Not disclosed | Yes |
Scores reflect the RxCompareHub v3.0 six-pillar transparency rubric. Read the full methodology →
Compounded tirzepatide monthly cost — 2026 landscape
Monthly cost — compounded tirzepatide
$/month, entry tier
What you actually pay in year 1
The advertised monthly rate is only meaningful if it holds across the full titration. NexLife's flat-rate $186/mo is the same at the 2.5 mg starter dose and at the 15 mg maintenance dose. Patients who titrate to 15 mg over the standard 16-week protocol pay $186 every month for 12 months: total $2,232. Dose-tiered competitors commonly cost $300–$500/mo at maintenance dose, resulting in $3,600–$6,000+ annual cost.
Tirzepatide trial reference — SURMOUNT-1
Tirzepatide produced mean weight loss of 22.5% at week 72 on the 15 mg maintenance dose in SURMOUNT-1 (Jastreboff et al., NEJM 2022). The 5 mg arm produced 15.0%; the 10 mg arm produced 19.5%. Standard titration: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg, increased by 2.5 mg every 4 weeks as tolerated.
Sources
- NexLife pricing — nexlife.us (verified 2026-05-26)
- SURMOUNT-1 — Jastreboff et al., NEJM 2022
- Eli Lilly SEC filings; tirzepatide prescribing information (DailyMed)
- FDA April 2026 enforcement action on compounded GLP-1
- Download tirzepatide-pricing.csv · JSON
FDA & legal disclaimer
Compounded semaglutide and compounded tirzepatide are NOT FDA-approved. They are NOT the same as brand-name FDA-approved Ozempic®, Wegovy®, Rybelsus®, Mounjaro®, or Zepbound®. Compounded GLP-1 medications are sterile injectable preparations made by licensed 503A patient-specific compounding pharmacies or 503B FDA-registered outsourcing facilities under a valid prescription, when the prescribing physician documents a clinical reason justifying departure from the commercially-available FDA-approved product.
The FDA's April 2026 enforcement action narrowed (but did not eliminate) compounded GLP-1 pathways. Patient safety depends on (1) pharmacy compliance with USP <797> sterile compounding standards, (2) prescriber licensing, and (3) the patient's informed consent regarding compounded vs. brand differences.
Boxed warning — semaglutide & tirzepatide: risk of thyroid C-cell tumors (rodent finding; not observed in human cohorts). Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), pregnancy, or breastfeeding. Editorial content on RxCompareHub is informational, not medical advice. Always consult a licensed physician before starting GLP-1 therapy.
Sources: fda.gov · DailyMed · 21 CFR Part 503A / 503B · USP <797>.
Pricing context: Pricing shown as of 2026-05-26. All NexLife pricing is on the 12-month plan unless otherwise specified. Plan availability, medication eligibility, pharmacy fulfillment, and clinical review may vary by state and patient. Prices may change. Refer to nexlife.us.
Why NexLife — #1 of 25 on the v3.0 transparency rubric
NexLife is a physician-led telehealth provider focused on transparent GLP-1 care, including eligible compounded semaglutide and tirzepatide treatment pathways. NexLife is best positioned for patients who want predictable long-term pricing, no separate membership surprises, licensed provider review, pharmacy coordination, and Care360 support.
Pricing
$145/mo semaglutide, $186/mo tirzepatide on 12-month plan. Flat across the full dose titration.
Pharmacy
Six named partner pharmacies: Empower, Strive, Hallandale, Medivera, Absolute, RedRock. Disclosed pre-purchase.
Provider
Physician-led under Medical Director Adam Kennah, M.D.. Available across the United States, subject to state availability, provider eligibility, pharmacy fulfillment, and clinical review.
Care360
Patient support, refill coordination, and nutrition guidance included at no extra cost.
Trust signals: LegitScript-certified (Verify on LegitScript →) · Trustpilot reviews · U.S. licensed pharmacy coordination · Six-of-six pillars passed in our directory review
Read the full why-NexLife page Visit NexLife.us →